PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
| Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE
October 24, 2013 | ISSUE NUMBER 323 VOL 11

Special Feature
The 12th Annual Pharm Exec Industry Audit
The Pharm Exec Industry Audit holds a unique position in the increasingly crowded field of data sets tracking industry performance. It adheres to a simple objective: to identify how well companies are doing in advancing shareholder value. For an overview of the metrics we used to assess company performance this year (and thus decide on our winner), click here ...Read more

Healthcare Reform
The Rx Industry, PBMs, and Obamacare
A significant, though as yet, not fully understood player in the launch of Obamacare is the “pharmacy benefit manager” (PBM) industry.  This uncertainty, due in part to the current Obamacare IT chaos, has more than a few Rx leaders worrying about how the PBMs tied to insurers in the program will end up impacting their businesses, writes Tom Norton ...Read more

PharmExec TV
GSK: Developing a Malaria Vaccine — Innovation and Partnership
At PhRMA’s Research and Hope Awards ceremony last month, Sophie Biernaux and Joe Cohen of GSK Vaccines spoke to PharmExec TV about their innovative approach to vaccine development ...Watch here

Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format.Tune In Now.

Healthcare IT
EMRs and Registries in the Era of Healthcare Reform
Advances in health information technology and new federal financial incentives are fueling rapid growth in the use of electronic medical record (EMR) systems. The key question for biopharma planners is finding the best way to leverage the capabilities of EMRs in tandem with patient registries
...Read more

New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle.Download Now

Marketing
In the Digital Age, Don’t Forget the Power of G.O.Y.A
Digital devices have made it possible to conduct business without ever leaving your desk. But something is just wrong with that, writes Al Topin, who here advocates how vital it is still, putting it plainly, to “get off your a**”
...Read more

Pharma’s Shift to Custom Solutions Marketing.
Leveraging Custom Digital Solutions to Engage Targeted Physician/HCP Audiences

Live Webinar: Thursday, October 31, 2013 at 11:00 am ET
Register Free at www.pharmexec.com/custom.

Marketing and Competition
Winning Pharma’s Super Conferences
Big Pharma’s versions of the Super Bowl are its “Super Conferences”, such as the American Society of Clinical Oncologists (ASCO) congress or the American Diabetes Association (ADA) meeting. How has pharma leveraged Competitive Conference Management at these events to gain competitive advantages and enhance product sales? Stan Bernard and Janet Wells report
...Read more

Integrated Strategies for Oncology Provider Engagement
Live Webcast: Wednesday, October 30, 2013 at 11:00 am EDT
Register Free at www.pharmexec.com/provider_engagement

//Dr Mark McClellan, the former Head of the Food and Drug Administration, has been elected to Merck’s Board of Directors.//Mylan Inc. (Pittsburgh, PA) appointed Jacek Glinka as President of its European business, effective December 2. Glinka will report to Hal Korman, Mylan's Chief Operating Officer.//Osmotica Pharmaceutical Corp. (Marietta, GA) announced the appointment of Kenneth Gayron as Vice President and Chief Financial Officer.//

November 13–14: Sponsor/CRO and Business Process Integration
Raleigh, NC.


November 13–15: 2013 HBA Leadership Conference
Boston, MA.


December 6: New York Pharma Forum's 24th Annual General Assembly
New York, NY.


January 28–29, 2014: 11th Annual Pharmaceutical Compliance Congress
Washington, DC.


 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook
Follow Pharm Exec on Linkedin

 

Survey
Should government funding for the US National Institutes of Health be exempted from federal budget sequestration cuts, debt ceiling negotiations and future government shutdowns?

Click To Vote
 

Quick Links

Taking Stock: Pharm Exec Editor-in-Chief William Looney On This Year’s Industry Audit

Washington Report: The Brand–Generic Wars Heat Up

The Future is Now: Leveraging Machine-to-Machine Technology to Advance Clinical Trials